 Patients with high-risk, locally advanced TxN2b3 or T4N03, M0 OSCC will be eligible. To detect an interested objective response rate p1 of 80 versus a non-interested response p0 rate of 60, with an α and 1-β of 0.05 and 0.2, respectively two-sided test, including the estimated dropout rate of 10, a total of 47 patients will be recruited. 